Opinion|Videos|May 7, 2025
Importance of Multispecialty Communication in Hypercortisolism Management and Referrals
Experts discuss the role of primary care clinicians in identifying and screening patients for hypercortisolism, how hypercortisolism affects mental health and how primary care clinicians can identify at-risk patients, and how hypercortisolism contributes to osteoporosis and an increased risk of fractures.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of primary care clinicians in identifying and screening patients for hypercortisolism?
- How does hypercortisolism affect mental health? How can primary care clinicians help identify patients with mental health conditions who might be at risk for hypercortisolism?
- How does hypercortisolism contribute to osteoporosis and an increased risk of fractures?
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement
Trending on HCPLive
1
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5